{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:08:53Z","timestamp":1788754133734,"version":"build-2803163510"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"none"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40272-024-00666-2","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:13:48Z","timestamp":1740068028000},"page":"331-349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Meningococcal Vaccination in the United States: Past, Present, And Future"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-840X","authenticated-orcid":false,"given":"Sarah","family":"Schillie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8240-7493","authenticated-orcid":false,"given":"Lucy A.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"666_CR1","doi-asserted-by":"publisher","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(No. RR-9):1\u201341. https:\/\/doi.org\/10.15585\/mmwr.rr6909a1.","DOI":"10.15585\/mmwr.rr6909a1"},{"key":"666_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.062","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012. https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.062.","journal-title":"Vaccine"},{"key":"666_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1451810","author":"AW Dretler","year":"2018","unstructured":"Dretler AW, Rouphael NG, Stephens DS. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. Human Vaccine Immunother. 2018. https:\/\/doi.org\/10.1080\/21645515.2018.1451810.","journal-title":"Human Vaccine Immunother."},{"key":"666_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","volume":"799","author":"NG Rouphael","year":"2012","unstructured":"Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1\u201320.","journal-title":"Methods Mol Biol"},{"key":"666_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2","author":"DS Stephens","year":"2007","unstructured":"Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007. https:\/\/doi.org\/10.1016\/S0140-6736(07)61016-2.","journal-title":"Lancet"},{"key":"666_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1258308","author":"R Borrow","year":"2017","unstructured":"Borrow R, Alarc\u00f3n P, Carlos J, et al. Global Meningococcal Initiative. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017. https:\/\/doi.org\/10.1080\/14760584.2017.1258308.","journal-title":"Expert Rev Vaccines"},{"key":"666_CR7","doi-asserted-by":"crossref","unstructured":"McNamara LA, Pollard AJ, Harrison LH. Meningococcal capsular group A, C, W, and Y conjugate vaccines. In: Orenstein WA, Offit PA, Edwards KM, Plotkin SA, editors. Plotkin\u2019s Vaccines 8th ed. 2022. p. 664\u201389.","DOI":"10.1016\/B978-0-323-79058-1.00039-6"},{"key":"666_CR8","unstructured":"McNamara LA, Blain A. Meningococcal disease. In: Manual for the Surveillance of Vaccine-Preventable Diseases. 2022. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt08-mening.html."},{"key":"666_CR9","unstructured":"Cohn AC, MacNeil JR, Clark TA, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1\u201328."},{"key":"666_CR10","unstructured":"Public Health Response for Outbreaks | Meningococcal | CDC. Accessed 6 May 2024."},{"key":"666_CR11","doi-asserted-by":"publisher","unstructured":"Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged \u226510 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73:345\u2013350. https:\/\/doi.org\/10.15585\/mmwr.mm7315a4.","DOI":"10.15585\/mmwr.mm7315a4"},{"key":"666_CR12","unstructured":"Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. In: Hall E, Wodi AP, Hamborsky J et al, editors. 14th ed. Washington, D.C.: Public Health Foundation; 2021."},{"key":"666_CR13","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268808000770","author":"MR Hoek","year":"2008","unstructured":"Hoek MR, Christensen H, Hellenbrand W, Stefanoff P, Howitz M, Stuart JM. Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review. Epidemiol Infect. 2008. https:\/\/doi.org\/10.1017\/S0950268808000770.","journal-title":"Epidemiol Infect"},{"key":"666_CR14","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819001134","author":"LV Cooper","year":"2019","unstructured":"Cooper LV, Kristiansen PA, Christensen H, Karachaliou A, Trotter CL. Meningococcal carriage by age in the African meningitis belt: a systematic review and meta-analysis. Epidemiol Infect. 2019. https:\/\/doi.org\/10.1017\/S0950268819001134.","journal-title":"Epidemiol Infect"},{"key":"666_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix993","author":"JR MacNeil","year":"2018","unstructured":"MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease-United States, 1996\u20132015. Clin Infect Dis. 2018. https:\/\/doi.org\/10.1093\/cid\/cix993.","journal-title":"Clin Infect Dis"},{"key":"666_CR16","doi-asserted-by":"publisher","first-page":"e979","DOI":"10.1542\/peds.2006-0281","volume":"118","author":"SL Kaplan","year":"2006","unstructured":"Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics. 2006;118:e979\u201384.","journal-title":"Pediatrics"},{"key":"666_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","volume":"367","author":"MJ Thompson","year":"2006","unstructured":"Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397\u2013403.","journal-title":"Lancet"},{"key":"666_CR18","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","volume":"344","author":"NE Rosenstein","year":"2001","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344:1378\u201388.","journal-title":"N Engl J Med"},{"key":"666_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1086\/313617","volume":"30","author":"JM Winstead","year":"2000","unstructured":"Winstead JM, McKinsey DS, Tasker S, et al. Meningococcal pneumonia: characterization and review of cases seen over the past 25 years. Clin Infect Dis. 2000;30:87\u201394.","journal-title":"Clin Infect Dis"},{"key":"666_CR20","unstructured":"American Academy of Pediatrics. Meningococcal Infections. In: Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH, editors. Red Book: 2024 Report of the Committee on infectious diseases. American Academy of Pediatrics; 2024. p. 585\u201399."},{"key":"666_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0035-9203(01)90007-0","volume":"95","author":"A Hodgson","year":"2001","unstructured":"Hodgson A, Smith T, Gagneux S, et al. Risk factors for meningococcal meningitis in northern Ghana. Trans R Soc Trop Med Hyg. 2001;95:477\u201380.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"666_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015493","volume":"5","author":"AR Tuite","year":"2010","unstructured":"Tuite AR, Kinlin LM, Kuster SP, et al. Respiratory virus infection and risk of invasive meningococcal disease in central Ontario, Canada. PLoS ONE. 2010;5: e15493.","journal-title":"PLoS ONE"},{"key":"666_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/00006454-199710000-00015","volume":"16","author":"M Fischer","year":"1997","unstructured":"Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979\u201383.","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 1","key":"666_CR24","first-page":"57","volume":"86","author":"P Densen","year":"1991","unstructured":"Densen P. Complement deficiencies and meningococcal disease. Clin and Exp Immunol. 1991;86(suppl 1):57\u201362.","journal-title":"Clin and Exp Immunol."},{"issue":"8","key":"666_CR25","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3201\/eid2408.180228","volume":"24","author":"D Nolfi-Donegan","year":"2018","unstructured":"Nolfi-Donegan D, Konar M, Vianzon V, et al. Fatal nongroupable Neisseria meningitidis disease in vaccinated patient receiving eculizumab. Emerg Infect Dis. 2018;24(8):1561\u20134. https:\/\/doi.org\/10.3201\/eid2408.180228.","journal-title":"Emerg Infect Dis"},{"key":"666_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/adc.86.3.215","volume":"86","author":"S Hoare","year":"2002","unstructured":"Hoare S, El-Shazali O, Clark JE, et al. Investigation for complement deficiency following meningococcal disease. Arch Dis Child. 2002;86:215\u20137.","journal-title":"Arch Dis Child"},{"issue":"2","key":"666_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0022-3476(89)80793-0","volume":"114","author":"M Nagata","year":"1989","unstructured":"Nagata M, Hara T, Aoki T, et al. Inherited deficiency of ninth component of complement: an increased risk of meningococcal meningitis. J Pediatr. 1989;114(2):260\u20134.","journal-title":"J Pediatr"},{"key":"666_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10875-014-0104-6","volume":"35","author":"M Daures","year":"2015","unstructured":"Daures M, John M, Balter CV, et al. Relationships between clinico-epidemiological patterns of invasive meningococcal infections and complement deficiencies in French South Pacific islands (New Caledonia). J Clin Immunol. 2015;35:47\u201355.","journal-title":"J Clin Immunol"},{"key":"666_CR29","doi-asserted-by":"publisher","unstructured":"Cohen C, Singh E, Wu HM, Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa (GERMS-SA), et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS 2010. https:\/\/doi.org\/10.1097\/QAD.0b013e32833a2520","DOI":"10.1097\/QAD.0b013e32833a2520"},{"key":"666_CR30","doi-asserted-by":"publisher","unstructured":"Bozio CH, Blain A, MacNeil J, et al. Meningococcal disease surveillance in men who have sex with men\u2014United States, 2015\u20132016. MMWR Morb Mortal Wkly Rep. 2018. https:\/\/doi.org\/10.15585\/mmwr.mm6738a4externalicon.","DOI":"10.15585\/mmwr.mm6738a4externalicon"},{"key":"666_CR31","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-160-1-201401070-00731","author":"L Miller","year":"2014","unstructured":"Miller L, Arakaki L, Ramautar A, et al. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med. 2014. https:\/\/doi.org\/10.7326\/0003-4819-160-1-201401070-00731.","journal-title":"Ann Intern Med"},{"key":"666_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.9.4811-4814.2005","author":"JJ Sejvar","year":"2005","unstructured":"Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory acquired meningococcal disease. J Clin Microbiol. 2005. https:\/\/doi.org\/10.1128\/JCM.43.9.4811-4814.2005.","journal-title":"J Clin Microbiol"},{"key":"666_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ597","author":"C Lingani","year":"2015","unstructured":"Lingani C, Bergeron-Caron C, Stuart JM, Fernandez K, Djingarey MH, Ronveaux O, Schnitzler JC, Perea WA. Meningococcal meningitis surveillance in the African Meningitis Belt, 2004\u20132013. Clin Infect Dis. 2015. https:\/\/doi.org\/10.1093\/cid\/civ597.","journal-title":"Clin Infect Dis"},{"key":"666_CR34","doi-asserted-by":"publisher","unstructured":"Bai X, Borrow R, Bukovski S, et al. Prevention and control of meningococcal disease: updates from the global meningococcal initiative in Eastern Europe. J Infect. 2019;79(6):528\u201341. https:\/\/doi.org\/10.1016\/j.jinf.2019.10.018.","DOI":"10.1016\/j.jinf.2019.10.018"},{"issue":"5","key":"666_CR35","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jinf.2020.07.025","volume":"81","author":"AMM Aye","year":"2020","unstructured":"Aye AMM, Bai X, Borrow R, et al. Meningococcal disease surveillance in the Asia-Pacific region (2020): the global meningococcal initiative. J Infect. 2020;81(5):698\u2013711. https:\/\/doi.org\/10.1016\/j.jinf.2020.07.025.","journal-title":"J Infect"},{"key":"666_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad607","author":"LW Weil","year":"2023","unstructured":"Weil LW, Crowe SJ, Rubis AB, et al. Risk factors for serogroup B meningococcal disease among college students. Open Forum Infect Dis. 2023. https:\/\/doi.org\/10.1093\/ofid\/ofad607.","journal-title":"Open Forum Infect Dis"},{"key":"666_CR37","unstructured":"Meningococcal Disease Surveillance and Trends. https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/index.html#:~:text=Disease%20trends%20since%202021,disease%20cases%20reported%20since%202014. Accessed 6 May 2024."},{"key":"666_CR38","unstructured":"Best practice guidelines for diagnosis of Haemophilus influenzae and Neisseria meningitidis disease https:\/\/www.cdc.gov\/meningococcal\/php\/guidance\/index.html. Accessed 6 May 2024."},{"key":"666_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac230","author":"KC Rudmann","year":"2022","unstructured":"Rudmann KC, Brown NE, Rubis AB, et al. Invasive meningococcal disease among people experiencing homelessness\u2014United States, 2016\u20132019. J Infect Dis. 2022. https:\/\/doi.org\/10.1093\/infdis\/jiac230.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"666_CR40","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/infdis\/165-Supplement_1-S49","volume":"165","author":"KE Stein","year":"1992","unstructured":"Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992;165(Suppl 1):S49-52. https:\/\/doi.org\/10.1093\/infdis\/165-Supplement_1-S49.","journal-title":"J Infect Dis"},{"key":"666_CR41","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1086\/344273","volume":"35","author":"JF Brundage","year":"2002","unstructured":"Brundage JF, Ryan MAK, Feighner BH, Erdtmann FJ. Meningococcal disease among United states military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964\u20131998. Clin Infect Dis. 2002;35:1376\u201381.","journal-title":"Clin Infect Dis"},{"key":"666_CR42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","volume":"159","author":"H Keyserling","year":"2005","unstructured":"Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159:907\u201313.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"666_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/01.inf.0000151035.64356.f8","volume":"24","author":"DM Granoff","year":"2005","unstructured":"Granoff DM, Morgan A, Welsch JA. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J. 2005;24:132\u20136.","journal-title":"Pediatr Infect Dis J"},{"key":"666_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0264-410X(92)90091-W","volume":"10","author":"P Costantino","year":"1992","unstructured":"Costantino P, Viti S, Podda A, et al. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 1992;10:691\u20138.","journal-title":"Vaccine"},{"key":"666_CR45","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/jama.280.19.1685","volume":"280","author":"NE MacDonald","year":"1998","unstructured":"MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA. 1998;280:1685\u20139.","journal-title":"JAMA"},{"key":"666_CR46","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1086\/314753","volume":"179","author":"P Richmond","year":"1999","unstructured":"Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999;179:1569\u201372.","journal-title":"J Infect Dis"},{"key":"666_CR47","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1001\/jama.283.21.2795","volume":"283","author":"JM MacLennan","year":"2000","unstructured":"MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283:2795\u2013801.","journal-title":"JAMA"},{"key":"666_CR48","unstructured":"Food and Drug Administration. Package insert: Menveo. Silver Spring: US Department of Health and Human Services, Food and Drug Administration; 2022. https:\/\/www.fda.gov\/media\/78514\/downloadhttps:\/\/www.fda.gov\/media\/89936\/download."},{"key":"666_CR49","unstructured":"Food and Drug Administration. Package insert: Menquadfi. Silver Spring: US Department of Health and Human Services, Food and Drug Administration; 2023. https:\/\/www.fda.gov\/media\/137306\/download."},{"key":"666_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taae002","author":"LA McNamara","year":"2024","unstructured":"McNamara LA, Neatherlin J. WHO Strategic Advisory Group of Experts on Immunization recommendations for use of a novel pentavalent meningococcal ACWXY vaccine: a critical step towards ending meningococcal epidemics in Africa. J Travel Med. 2024. https:\/\/doi.org\/10.1093\/jtm\/taae002.","journal-title":"J Travel Med"},{"key":"666_CR51","unstructured":"Summary of Product Characteristics. https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadSmPC\/SmPC%20of%20MenFive%20%20vaccine%20of%20of%20Ms%20Serum%20Institute%20India%20Pvt%20Ltd.pdf. Accessed 15 May 2024."},{"key":"666_CR52","unstructured":"Serum Institute of India Pvt. Ltd. Multivalent meningococcal meningitis vaccine from Serum Institute of India achieves WHO prequalification. 2023. https:\/\/www.seruminstitute.com\/press_release_sii_120723.php. Accessed 8 June 2024."},{"key":"666_CR53","doi-asserted-by":"crossref","unstructured":"Stephens DS, Granoff DM, Pollard AJ, Harrison LH, editors. Chapter 40, Meningococcal Vaccines Directed at Capsular Group B. p. 690\u2013710.","DOI":"10.1016\/B978-0-323-79058-1.00040-2"},{"key":"666_CR54","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","author":"M Pizza","year":"2000","unstructured":"Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287:1816\u201320.","journal-title":"Science"},{"key":"666_CR55","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1084\/jem.185.7.1173","volume":"185","author":"D Martin","year":"1997","unstructured":"Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med. 1997;185:1173\u201383.","journal-title":"J Exp Med"},{"key":"666_CR56","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","volume":"281","author":"JW Tappero","year":"1999","unstructured":"Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999;281:1520\u20137.","journal-title":"JAMA"},{"key":"666_CR57","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1086\/315833","volume":"182","author":"CT Sacchi","year":"2000","unstructured":"Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992\u20131998. J Infect Dis. 2000;182:1169\u201376.","journal-title":"J Infect Dis"},{"key":"666_CR58","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/aje\/kwm147","volume":"166","author":"C Kelly","year":"2007","unstructured":"Kelly C, Arnold R, Galloway Y, O\u2019Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007;166:817\u201323.","journal-title":"Am J Epidemiol"},{"key":"666_CR59","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","volume":"25","author":"H Nokleby","year":"2007","unstructured":"Nokleby H, Aavitsland P, O\u2019Hallahan J, et al. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine. 2007;25:3080\u20134.","journal-title":"Vaccine"},{"key":"666_CR60","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","volume":"29","author":"R Arnold","year":"2011","unstructured":"Arnold R, Galloway Y, McNicholas A, O\u2019Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011;29:7100\u20136.","journal-title":"Vaccine"},{"issue":"17\u201318","key":"666_CR61","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","author":"P Oster","year":"2005","unstructured":"Oster P, Lennon D, O\u2019Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23(17\u201318):2191\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2005.01.063.","journal-title":"Vaccine"},{"key":"666_CR62","doi-asserted-by":"publisher","DOI":"10.37757\/MR2019.V21.N4.4","author":"G Sierra-Gonz\u00e1lez","year":"2019","unstructured":"Sierra-Gonz\u00e1lez G. Cuban meningococcal vaccine VA-MENGOC-BC:30 years of use and future potential. MEDICC Rev. 2019. https:\/\/doi.org\/10.37757\/MR2019.V21.N4.4.","journal-title":"MEDICC Rev"},{"key":"666_CR63","doi-asserted-by":"publisher","unstructured":"McNeil L, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. mBio. 2018. https:\/\/doi.org\/10.1128\/mbio.00036-18.","DOI":"10.1128\/mbio.00036-18"},{"key":"666_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00261-17","author":"G Rajam","year":"2017","unstructured":"Rajam G, Stella M, Kim E, et al. Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States. mSphere. 2017. https:\/\/doi.org\/10.1128\/msphere.00261-17.","journal-title":"mSphere"},{"key":"666_CR65","unstructured":"GSK\u2019s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA | GSK."},{"key":"666_CR66","unstructured":"https:\/\/www.cdc.gov\/vaccines\/schedules\/index.html."},{"key":"666_CR67","unstructured":"https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html."},{"key":"666_CR68","doi-asserted-by":"publisher","unstructured":"Schillie S, Loehr J, Chen WH, et al. New dosing interval and schedule for the bexsero MenB-4C vaccine: updated recommendations of the advisory committee on immunization practices \u2014 United States, October 2024. MMWR Morb Mortal Wkly Rep 2024;73:1124\u201328. https:\/\/doi.org\/10.15585\/mmwr.mm7349a3.","DOI":"10.15585\/mmwr.mm7349a3"},{"key":"666_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00444-3","author":"J Mueller","year":"2023","unstructured":"Mueller J. Serogroup B meningococcal vaccines from the public health perspective. Lancet. 2023. https:\/\/doi.org\/10.1016\/S1473-3099(22)00444-3.","journal-title":"Lancet"},{"key":"666_CR70","unstructured":"VAERS | Vaccine Safety | CDC https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vaers\/index.html."},{"key":"666_CR71","unstructured":"CDC. Update: Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine\u2014United States, June 2005\u2013September 2006. MMWR Morb Mortal Wkly Rep. 2006;55:1120\u20134."},{"key":"666_CR72","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/pds.3353","volume":"21","author":"WK Yih","year":"2012","unstructured":"Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barr\u00e9 syndrome found after meningococcal conjugate vaccination in two large cohort studies. Pharmacoepidemiol Drug Saf. 2012;21:1359\u201360. https:\/\/doi.org\/10.1002\/pds.3353.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"666_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3321","author":"P Velentgas","year":"2012","unstructured":"Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barr\u00e9 syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012. https:\/\/doi.org\/10.1002\/pds.3321.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"666_CR74","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2084","author":"HF Tseng","year":"2017","unstructured":"Tseng HF, Sy LS, Ackerson BK, et al. Safety of quadrivalent meningococcal conjugate vaccine in 11- to 21-year-olds. Pediatrics. 2017. https:\/\/doi.org\/10.1542\/peds.2016-2084.","journal-title":"Pediatrics"},{"key":"666_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.071","author":"S Perez-Vilar","year":"2022","unstructured":"Perez-Vilar S, Dores GM, Marquez PL, et al. Safety surveillance of meningococcal group B vaccine (Bexsero\u00ae), vaccine adverse event reporting system, 2015\u20132018. Vaccine. 2022. https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.071.","journal-title":"Vaccine"},{"key":"666_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa516","author":"J Duffy","year":"2020","unstructured":"Duffy J, Marquez P, Dores GM, et al. Safety surveillance of bivalent meningococcal group B vaccine, Vaccine Adverse Event Reporting System, 2014\u20132018. Open Forum Infect Dis. 2020. https:\/\/doi.org\/10.1093\/ofid\/ofaa516.","journal-title":"Open Forum Infect Dis"},{"key":"666_CR77","doi-asserted-by":"publisher","DOI":"10.1080\/07448481.2017.1312418","author":"J Duffy","year":"2017","unstructured":"Duffy J, Johnsen P, Ferris M, et al. Safety of a meningococcal group B vaccine used in response to two university outbreaks. J Am Coll Health. 2017. https:\/\/doi.org\/10.1080\/07448481.2017.1312418.","journal-title":"J Am Coll Health"},{"key":"666_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.051","author":"R Borrow","year":"2005","unstructured":"Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection\u2014serum bactericidal antibody activity. Vaccine. 2005. https:\/\/doi.org\/10.1016\/j.vaccine.2005.01.051.","journal-title":"Vaccine"},{"key":"666_CR79","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969. https:\/\/doi.org\/10.1084\/jem.129.6.1307.","journal-title":"J Exp Med"},{"key":"666_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.063","author":"LM Huang","year":"2014","unstructured":"Huang LM, Chiu NC, Yeh SJ, Bhusal C, Arora AK. Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2\u201318 years in Taiwan: results of an open label study. Vaccine. 2014. https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.063.","journal-title":"Vaccine"},{"key":"666_CR81","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29571","author":"N Ilyina","year":"2014","unstructured":"Ilyina N, Kharit S, Namazova-Baranova L, et al. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia. Hum Vaccin Immunother. 2014. https:\/\/doi.org\/10.4161\/hv.29571.","journal-title":"Hum Vaccin Immunother"},{"key":"666_CR82","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31818a0237","author":"LA Jackson","year":"2009","unstructured":"Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009. https:\/\/doi.org\/10.1097\/INF.0b013e31818a0237.","journal-title":"Pediatr Infect Dis J"},{"key":"666_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.017","author":"L-J Chang","year":"2020","unstructured":"Chang L-J, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020. https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.017.","journal-title":"Vaccine"},{"key":"666_CR84","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.11.12849","author":"CJ Gill","year":"2010","unstructured":"Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents. Hum Vaccin. 2010. https:\/\/doi.org\/10.4161\/hv.6.11.12849.","journal-title":"Hum Vaccin"},{"key":"666_CR85","doi-asserted-by":"crossref","unstructured":"Peterson JH, Pan J, Neveu D, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) administered in adolescents 10\u201317 years of age. In: Presented at the Infectious Diseases Society of America meeting, Washington, DC; October 2\u20136, 2019.","DOI":"10.1093\/ofid\/ofz360.2400"},{"key":"666_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.02.025","author":"R Baxter","year":"2014","unstructured":"Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J Pediatr. 2014. https:\/\/doi.org\/10.1016\/j.jpeds.2014.02.025.","journal-title":"J Pediatr"},{"key":"666_CR87","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","volume":"33","author":"R Baxter","year":"2014","unstructured":"Baxter R, Reisinger K, Block SL, et al. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr Infect Dis J. 2014;33:1169\u201376. https:\/\/doi.org\/10.1097\/INF.0000000000000438.","journal-title":"Pediatr Infect Dis J"},{"key":"666_CR88","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318279ac38","author":"RM Jacobson","year":"2013","unstructured":"Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. 2013. https:\/\/doi.org\/10.1097\/INF.0b013e318279ac38.","journal-title":"Pediatr Infect Dis J"},{"key":"666_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.08.065","author":"M Tipton","year":"2019","unstructured":"Tipton M, Daly W, Senders S, et al. MenACWY-CRM conjugate vaccine booster dose given 4\u20136 years after priming: results from a phase IIIb, multicenter, open label study in adolescents and adults. Vaccine. 2019. https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.065.","journal-title":"Vaccine"},{"key":"666_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.073","author":"T Vesikari","year":"2019","unstructured":"Vesikari T, \u00d8stergaard L, Beeslaar J, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019. https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.073.","journal-title":"Vaccine"},{"key":"666_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.071","author":"RC Read","year":"2017","unstructured":"Read RC, Dull P, Bai X, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2017. https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.071.","journal-title":"Vaccine"},{"key":"666_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61713-3","author":"ME Santolaya","year":"2012","unstructured":"Santolaya ME, O\u2019Ryan ML, Valenzuela MT, et al. V72P10 Meningococcal B Adolescent Vaccine Study Group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012. https:\/\/doi.org\/10.1016\/S0140-6736(11)61713-3.","journal-title":"Lancet"},{"key":"666_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30314-0","author":"HS Marshall","year":"2017","unstructured":"Marshall HS, Richmond PC, Beeslaar J, et al. 6108A12001 Study Investigators. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2017. https:\/\/doi.org\/10.1016\/S1473-3099(16)30314-0.","journal-title":"Lancet Infect Dis"},{"key":"666_CR94","unstructured":"ClinicalTrials.gov. Phase 2, observer-blind, placebo-controlled, randomized, multi-center extension study to evaluate the safety and immunogenicity of a booster dose of a MenABCWY vaccine administered 24 months following the primary series to adolescents and young adults who participated in V102_03 (NCT01992536); 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01992536?term=NCT01992536&rank=1."},{"key":"666_CR95","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","volume":"37","author":"T Nolan","year":"2019","unstructured":"Nolan T, Santolaya ME, de Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37:1209\u201318. https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.059.","journal-title":"Vaccine"},{"issue":"12","key":"666_CR96","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1473-3099(23)00191-3","volume":"23","author":"J Peterson","year":"2023","unstructured":"Peterson J, Drazan D, Czajka H, et al. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial. Lancet Infect Dis. 2023;23(12):1370\u201382. https:\/\/doi.org\/10.1016\/S1473-3099(23)00191-3.","journal-title":"Lancet Infect Dis"},{"key":"666_CR97","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","volume":"383","author":"DM Daugla","year":"2014","unstructured":"Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet. 2014;383:40\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(13)61612-8.","journal-title":"Lancet"},{"key":"666_CR98","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/cid\/cis892","volume":"56","author":"PA Kristiansen","year":"2013","unstructured":"Kristiansen PA, Diomand\u00e9 F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354\u201363. https:\/\/doi.org\/10.1093\/cid\/cis892.","journal-title":"Clin Infect Dis"},{"key":"666_CR99","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"MC Maiden","year":"2008","unstructured":"Maiden MC, Ibarz-Pav\u00f3n AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737\u201343. https:\/\/doi.org\/10.1086\/527401.","journal-title":"J Infect Dis"},{"key":"666_CR100","doi-asserted-by":"publisher","unstructured":"McMillan M, Chandrakumar A, Wang HLR, et al. Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal neisseria meningitidis carriage: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(3):e609\u201319. https:\/\/doi.org\/10.1093\/cid\/ciaa1733.","DOI":"10.1093\/cid\/ciaa1733"},{"key":"666_CR101","doi-asserted-by":"publisher","unstructured":"Carr JP, MacLennan JM, Plested E, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28(12):1649.e1\u20138. ISSN: 1198-743X. https:\/\/doi.org\/10.1016\/j.cmi.2022.07.004.","DOI":"10.1016\/j.cmi.2022.07.004"},{"key":"666_CR102","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","volume":"382","author":"HS Marshall","year":"2020","unstructured":"Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Eng L Med. 2020;382:318\u201327.","journal-title":"N Eng L Med"},{"key":"666_CR103","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123\u201331.","journal-title":"Lancet"},{"key":"666_CR104","doi-asserted-by":"publisher","unstructured":"McNamara LA, Thomas JD, MacNeil J, et al. oregon meningococcal carriage team, meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a University Serogroup B Meningococcal disease outbreak\u2014Oregon, 2015\u20132016. J Infect Dis. 2017;216(9):1130\u201340. https:\/\/doi.org\/10.1093\/infdis\/jix446.","DOI":"10.1093\/infdis\/jix446"},{"key":"666_CR105","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/cix091","volume":"64","author":"HM Soeters","year":"2017","unstructured":"Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college-Rhode Island, 2015\u20132016. Clin Infect is. 2017;64:1115\u201322.","journal-title":"Clin Infect is"},{"issue":"2","key":"666_CR106","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2193","volume":"139","author":"AC Cohn","year":"2017","unstructured":"Cohn AC, MacNeil JR, Harrison LH, Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2): e20162193. https:\/\/doi.org\/10.1542\/peds.2016-2193.","journal-title":"Pediatrics"},{"issue":"11","key":"666_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187466","volume":"12","author":"AO Diallo","year":"2017","unstructured":"Diallo AO, Soeters HM, Yameogo I, et al. Bacteria meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign. PLoS ONE. 2017;12(11): e0187466.","journal-title":"PLoS ONE"},{"issue":"Suppl 4","key":"666_CR108","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.1093\/infdis\/jiz336","volume":"220","author":"A Bwaka","year":"2019","unstructured":"Bwaka A, Bita A, Lingani C, et al. Status of the rollout of the meningococcal serogroup A conjugate vaccine in African meningitis belt countries in 2018. J Infect Dis. 2019;220(Suppl 4):S140\u20137.","journal-title":"J Infect Dis"},{"key":"666_CR109","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","volume":"364","author":"CL Trotter","year":"2004","unstructured":"Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365\u20137.","journal-title":"Lancet"},{"issue":"suppl 2","key":"666_CR110","doi-asserted-by":"publisher","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","volume":"27","author":"H Campbell","year":"2009","unstructured":"Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(suppl 2):B20\u20139.","journal-title":"Vaccine"},{"issue":"9","key":"666_CR111","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamapediatrics.2020.1990","volume":"174","author":"S Mbaeyi","year":"2020","unstructured":"Mbaeyi S, Pondo T, Blain A, et al. Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. JAMA Pediatr. 2020;174(9):843\u201351. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.1990.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"666_CR112","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3201\/eid2503.181574","volume":"25","author":"HM Soeters","year":"2019","unstructured":"Soeters HM, McNamara LA, Blain AE, et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013\u20132018. Emerg Infect Dis. 2019;25(3):434\u201340.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"666_CR113","doi-asserted-by":"publisher","first-page":"e00430","DOI":"10.1128\/CVI.00430-16","volume":"24","author":"S Giuntini","year":"2017","unstructured":"Giuntini S, Lujan E, Gabini MM, et al. Serum bactericidal antibody responses of adults immunized with the MenB-4C vaccine against genetically diverse serogroup B meningococci. Clin Vaccine Immunol. 2017;24(1):e00430-e516.","journal-title":"Clin Vaccine Immunol"},{"key":"666_CR114","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1901229","volume":"382","author":"S Ladhani","year":"2020","unstructured":"Ladhani S, Andrews N, Parikh S, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382:309\u201317.","journal-title":"N Engl J Med"},{"key":"666_CR115","doi-asserted-by":"crossref","unstructured":"Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: a Meningococcal Vaccines Directed at Capsular Group B five-year retrospective observational study (2014\u20132018). Vaccines (Basel). 2020;8(3).","DOI":"10.3390\/vaccines8030469"},{"key":"666_CR116","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.1016\/j.vaccine.2021.11.035","volume":"39","author":"AE Blain","year":"2021","unstructured":"Blain AE, Reese HE, Marjuki H, Topaz N, Mbaeyi S, McNamara LA. Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine\u2014United States, 2014\u20132018. Vaccine. 2021;39:7541\u20134.","journal-title":"Vaccine"},{"key":"666_CR117","doi-asserted-by":"publisher","first-page":"7655","DOI":"10.1016\/j.vaccine.2021.11.004","volume":"39","author":"HE Reese","year":"2021","unstructured":"Reese HE, McNamara LA, Vianzon V, et al. Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine\u2014United States, 2014\u20132019. Vaccine. 2021;39:7655\u201360.","journal-title":"Vaccine"},{"key":"666_CR118","unstructured":"Role of the Advisory Committee on Immunization Practices in CDC\u2019s Vaccine Recommendations. https:\/\/www.cdc.gov\/vaccines\/acip\/committee\/role-vaccine-recommendations.html. Accessed 15 May 2024."},{"key":"666_CR119","unstructured":"Centers for Disease Control and Prevention. Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(No. RR-7):[1\u201321]."},{"key":"666_CR120","unstructured":"Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines\u2014Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2011;60:72\u201377."},{"key":"666_CR121","doi-asserted-by":"crossref","unstructured":"MacNeil JR, Robin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin S. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1171\u20131176.","DOI":"10.15585\/mmwr.mm6441a3"},{"key":"666_CR122","unstructured":"Schillie S. ACIPPresentation: Revising the adolescent meningococcal vaccine schedule: Term of reference and considerations. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2024-02-28-29\/02-Meningitis-Schillie-508.pdf. Accessed 15 May 2024."},{"key":"666_CR123","doi-asserted-by":"publisher","unstructured":"Pingali C, Yankey D, Chen M, et al. National vaccination coverage among adolescents aged 13\u201317 years\u2014National Immunization Survey-Teen, United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73:708\u2013714. https:\/\/doi.org\/10.15585\/mmwr.mm7333a1.","DOI":"10.15585\/mmwr.mm7333a1"},{"key":"666_CR124","unstructured":"ACIP Shared Clinical Decision-Making Recommendations. https:\/\/www.cdc.gov\/vaccines\/acip\/acip-scdm-faqs.html#when-scdm. Accessed 15 May 2024."},{"key":"666_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.02.051","author":"CA Gidengil","year":"2023","unstructured":"Gidengil CA, Parker AM, Markowitz LE, et al. Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27\u201345 years in the United States. Vaccine. 2023. https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.051.","journal-title":"Vaccine"},{"key":"666_CR126","doi-asserted-by":"publisher","unstructured":"Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:793\u2013801. https:\/\/doi.org\/10.15585\/mmwr.mm7229a4","DOI":"10.15585\/mmwr.mm7229a4"},{"key":"666_CR127","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1682845","author":"L Huang","year":"2020","unstructured":"Huang L, Goren A, Lee LK, Li VW, Dempsey A, Srivastava A. Disparities in healthcare providers\u2019 interpretations and implementations of ACIP\u2019s meningococcal vaccine recommendations. Hum Vaccin Immunother. 2020. https:\/\/doi.org\/10.1080\/21645515.2019.1682845.","journal-title":"Hum Vaccin Immunother"},{"issue":"10102","key":"666_CR128","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","volume":"390","author":"H Petousis-Harris","year":"2017","unstructured":"Petousis-Harris H, Paynter J, Morgan J, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(17)31449-6.","journal-title":"Lancet"},{"key":"666_CR129","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrmicro2097","volume":"7","author":"M Virji","year":"2009","unstructured":"Virji M. Pathogenic neisseriae: surface modulation, pathogenesis and infection control. Nat Rev Microbiol. 2009;7:274\u201386.","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"666_CR130","first-page":"109","volume":"93","author":"CR Tinsley","year":"1996","unstructured":"Tinsley CR, Nassif X. Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two different pathogenicities. Proc Natl Acad Sci USA. 1996;93(11):109\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"666_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008602","volume":"16","author":"I Leduc","year":"2020","unstructured":"Leduc I, Connolly K, Begum A, et al. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. PLoS Pathog. 2020;16(12): e1008602.","journal-title":"PLoS Pathog"},{"key":"666_CR132","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/vaccines7010005","volume":"7","author":"J Paynter","year":"2019","unstructured":"Paynter J, Goodyear-Smith F, Morgan J, Saxton P, Black S, Petousis-Harris H. Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study. Vaccines. 2019;7:5. https:\/\/doi.org\/10.3390\/vaccines7010005.","journal-title":"Vaccines"},{"key":"666_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00754-4","author":"B Wang","year":"2022","unstructured":"Wang B, Giles L, Andraweera P, et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect Dis. 2022. https:\/\/doi.org\/10.1016\/S1473-3099(21)00754-4.","journal-title":"Lancet Infect Dis"},{"key":"666_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00812-4","author":"WE Abara","year":"2022","unstructured":"Abara WE, Bernstein KT, Lewis FMT, et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect Dis. 2022. https:\/\/doi.org\/10.1016\/S1473-3099(21)00812-4.","journal-title":"Lancet Infect Dis"},{"key":"666_CR135","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac436","author":"KJ Bruxvoort","year":"2023","unstructured":"Bruxvoort KJ, Lewnard JA, Chen LH, et al. Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in southern California. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciac436.","journal-title":"Clin Infect Dis"},{"key":"666_CR136","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx180.002","author":"J Longtin","year":"2017","unstructured":"Longtin J, Dion R, Simard M, et al. Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada. Open Forum Infect Dis. 2017. https:\/\/doi.org\/10.1093\/ofid\/ofx180.002.","journal-title":"Open Forum Infect Dis"},{"key":"666_CR137","unstructured":"Melville NA. Meningococcal Vaccine Shows Benefit in STI Prevention (medscape.com). In: Medscape Public Health. 2023. https:\/\/www.medscape.com\/viewarticle\/988588. Accessed 15 May 2024."},{"key":"666_CR138","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1381810","author":"H Petousis-Harris","year":"2018","unstructured":"Petousis-Harris H. Impact of meningococcal group B OMV vaccines, beyond their brief. Human Vaccine Immunother. 2018. https:\/\/doi.org\/10.1080\/21645515.2017.1381810.","journal-title":"Human Vaccine Immunother."},{"key":"666_CR139","unstructured":"Drug-Resistant Gonorrhea: A Public Health Threat (cdc.gov). https:\/\/www.cdc.gov\/std\/gonorrhea\/drug-resistant\/public-health-threat\/public-health-threat-text-only.htm#:~:text=Gonorrhea%20is%20the%20second%20most,to%20at%20least%20one%20antibiotic. Accessed 15 May 2024."},{"key":"666_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00031-8","author":"SN Ladhani","year":"2024","unstructured":"Ladhani SN, White PJ, Capbell H, et al. Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhea in the UK. Lancet Infect Dis. 2024. https:\/\/doi.org\/10.1016\/S1473-3099(24)00031-8.","journal-title":"Lancet Infect Dis"},{"key":"666_CR141","unstructured":"BexseroPackageInsert. https:\/\/www.fda.gov\/media\/90996\/download."},{"key":"666_CR142","doi-asserted-by":"publisher","unstructured":"Carrico J, La EM, Talbird SE, et al. Value of the immunization program for children in the 2017 US birth cohort. Pediatrics. 2022. https:\/\/doi.org\/10.1542\/peds.2021-056007.","DOI":"10.1542\/peds.2021-056007"},{"key":"666_CR143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002461","author":"MP Connolly","year":"2023","unstructured":"Connolly MP, Kotsopoulos N, Roberts C, et al. Public economic gains from tax-financed investments in childhood immunization in the United States. PLOS Glob Public Health. 2023. https:\/\/doi.org\/10.1371\/journal.pgph.0002461.","journal-title":"PLOS Glob Public Health."},{"key":"666_CR144","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00367-6","author":"J Amdahl","year":"2021","unstructured":"Amdahl J, Weycker D, Farkouh R, Huang L, Eichten C, Oster G. Pediatric vaccines and cost-effectiveness thresholds: how much is too much to pay for prevention? Infect Dis Ther. 2021. https:\/\/doi.org\/10.1007\/s40121-020-00367-6.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"666_CR145","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1542\/peds.2006-1573","volume":"119","author":"DB Rein","year":"2007","unstructured":"Rein DB, Hicks KA, Wirth KE. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics. 2007;119(1):e12-21. https:\/\/doi.org\/10.1542\/peds.2006-1573.","journal-title":"Pediatrics"},{"key":"666_CR146","unstructured":"Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-7): 1\u201323."},{"key":"666_CR147","doi-asserted-by":"crossref","unstructured":"Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices\u2014https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7103a2.htm United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:80\u201384.","DOI":"10.15585\/mmwr.mm7103a2"},{"key":"666_CR148","doi-asserted-by":"publisher","unstructured":"Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus\u2013associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1115\u20131122. https:\/\/doi.org\/10.15585\/mmwr.mm7241e1.","DOI":"10.15585\/mmwr.mm7241e1"},{"key":"666_CR149","unstructured":"Centers for Disease Control and Prevention. Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2013;62(No. RR-#): 1\u201328"},{"key":"666_CR150","unstructured":"Meyer SA. Epidemiology of meningococcal disease among college students\u2014United States, 2014\u20132016. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; February 22, 2018. https:\/\/stacks.cdc.gov\/view\/cdc\/59918. Accessed 15 May 2024."},{"key":"666_CR151","doi-asserted-by":"crossref","unstructured":"Smith JC. The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP). Vaccine. 28S (2010) A68\u2013A75.","DOI":"10.1016\/j.vaccine.2010.02.037"},{"key":"666_CR152","unstructured":"Smith JC, Hinman AR, Pickering Al. History and evolution of the Advisory Committee on Immunization Practices\u2014United States, 1964\u20132014 Report title. MMWR. 2014;63: 955\u201358."},{"issue":"51","key":"666_CR153","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1016\/j.vaccine.2013.08.008","volume":"31","author":"S Black","year":"2013","unstructured":"Black S. The role of health economic analyses in vaccine decision making. Vaccine. 2013;31(51):6046\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.008.","journal-title":"Vaccine"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00666-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:08:09Z","timestamp":1745582889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00666-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":153,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00666-2","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"4 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external sources of funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S.S. and L.M. have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"S.S. created the concept, performed writing of the first draft and revisions, and granted approval; L.M. created the concept, reviewed the first draft, provided revisions, and granted approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The manuscript has no associated data to be deposited.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}